Managing Toxicity in Later-Line HER2+ mBC Treatments: Real-World Insights and Mitigation Strategies for Optimal Patient QOLs
Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on the Cleopatra regimen with taxane, Trastuzumab, and Pertuzumab, and 11 months on Tdxd. As her disease is now progressing, so she needs 3rd line treatment. But despite some fatigue, she remains active with work and Yoga and her brain, MRIs are clear.
Video content above is prompted by the following:
- Please explore key clinical trial data findings, emphasizing perspectives around clinical safety and efficacy.
Recent Videos
Related Content
